EGFR and non-small cell lung carcinoma: However, the responses of EGFR-mutant NSCLC patients to EGFR TKIs are rarely complete with variable duration (Kobayashi et al., 2005; Rosell et al., 2012), suggesting that other factors could modulate the dependency of mutant EGFR and thus influencing EGFR TKI efficacy.